A promising medicine doesn’t always start with a new molecule. Researchers often revisit existing natural substances to explore new therapeutic uses. At Macau University of Science and Technology and Hangzhou Normal University, scientists examined curcumenol, a compound derived from Curcuma wenyujin, as a possible lung cancer treatment. Although prior studies had looked at its anticancer effects in other cancers, this research focused specifically on lung cancer. They tested curcumenol on six lung cancer cell lines, finding that five showed decreased survival at higher doses, while one, H1650, was less affected. Experiments with H460 and H1299 cells revealed that higher concentrations reduced colony formation and increased apoptosis. The study then progressed to animal models, where mice with H460 tumors treated with curcumenol experienced slower tumor growth and smaller tumors compared to controls, without significant weight changes. The data, especially in Figure 3C on page 12, show the growing difference in tumor size over time. While these early results do not confirm curcumenol as a treatment for lung cancer, they highlight an essential aspect of medical innovation: sometimes, progress comes not from discovering new molecules, but from finding new uses for natural compounds already available.
Could a familiar natural compound begin a new journey against lung cancer?
Patent number: CN 113181166 B
Inventor(s): Q. Wu, X. Sui, R. Zhang, and X. Wang
Citation: Q. Wu, X. Sui, R. Zhang, and X. Wang, “莪术烯醇在制备抗肺癌药物中的应用 [Application of curcumenol in preparing an anti-lung-cancer drug],” China Patent CN 113181166 B, Jan. 5, 2024.
